Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas (NOHARM-MTD)
Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
Sponsor: Children's Hospital Medical Center, Cincinnati
A PHASE3 clinical study on Malaria and Sickle Cell Anemia, this trial is completed. The trial is conducted by Children's Hospital Medical Center, Cincinnati and has accumulated 9 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Nov 2018 — Sep 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Hospital Medical Center, Cincinnati
- Doris Duke Charitable Foundation
- Indiana University
- Makerere University
- Mulago Hospital, Uganda
For direct contact, visit the study record on ClinicalTrials.gov .